Pharmaceuticals

A novel drug, LM11A-31, paired with advanced brain mapping, shows promise by preserving neural networks, marking a potential shift from targeting plaques.

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

This Monday, Q32 Bio will unveil pivotal data for its alopecia areata drug. For 700,000 Americans, it could mean a new path beyond today's treatments.

MindRank's AI platform propelled a GLP-1 drug to Phase III in record time. Its new $52M funding aims to prove this isn't a one-off, but a revolution.

The biotech's complex warrant restructuring is more than a balance sheet clean-up; it's a strategic masterstroke paving the way for its MASH drug.

Rani Therapeutics partners with PegBio, betting its drug-injecting capsule can unlock novel oral obesity therapies and challenge market giants.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

As the 340B drug pricing program grows more complex, safety-net providers are losing vital funds. A new approach urges independent oversight to stop the leakage.

Amplia Therapeutics' new patent application for novel FAK inhibitors extends protection to 2046, signaling a major play in oncology and fibrosis markets.

Vera Therapeutics just secured its first drug approval. Now, it's bringing in a regulatory heavyweight. We deconstruct the strategy behind the move.

Foresee Pharmaceuticals signals a major shift to commercialization, appointing Brian J. Groch to lead the launch of its 6-month CPP treatment, FP-001.

As India confronts a metabolic health crisis, a new care paradigm is emerging. Ajanta Pharma's latest move signals a larger trend: the future is not just a pill, but a personalized, digital ecosystem.

With a landmark NEJM publication and FDA approval, Rhythm Pharma's setmelanotide offers hope for a rare obesity, proving a potent strategy for niche markets.

Ultragenyx bets 62% of its budget on R&D while unprofitable. Its new Impact Report reveals a strategy where patient access and ESG are the real assets.

Supplement giant Niagen Bioscience is betting big on a new drug for a rare disease. Can its NAD+ science make the leap from wellness to a real cure?

With a PDUFA date set, Arcutis' ZORYVE could soon offer a once-daily, non-steroidal cream for infants, addressing a massive unmet need for families.

With record Q1 sales and key milestones for iDose® TR and Epioxa, all eyes are on Glaukos's July 29 financial release for its next growth chapter.

Keenova Therapeutics' positive Phase 3 results for XIAFLEX could bring the first-ever approved drug for plantar fibromatosis, a painful, disabling condition.

For families battling Duchenne, treatment is a daily trade-off. Now, a new drug class promises to ease this burden, signaling a new era for rare disease care.

After a clinical hold on its lead drug, Quantum BioPharma is spending heavily on marketing. Is it a bold play for survival or a sign of desperation?